mTOR inhibitor-associated dermatologic and mucosal problems.
Mammalian target of rapamycin inhibitor use is associated with numerous adverse events, including dermatologic and mucosal problems. Awareness of these complications, which clinically manifest across a severity spectrum from minor through severe and may occur at varied time points after initiation of sirolimus therapy, can be useful to clinicians in both managing these events and determining the appropriate intervention(s) for patients. This manuscript examines the dermatologic and mucosal problems associated with mammalian target of rapamycin inhibitor use, reviews the literature, and provides personal experiences regarding the management and treatment of these adverse events.
Campistol
Josep M
JM
Department of Urology and Nephrology, Hospital Clinic i Provincial, Barcelona, Spain.
de Fijter
Johan W
JW
Flechner
Stuart M
SM
Langone
Anthony
A
Morelon
Emmanuel
E
Stockfleth
Eggert
E
D000152:Acne Vulgaris / Q000139:chemically induced; D000465:Algorithms; D065095:Calcineurin Inhibitors; D005076:Exanthema / Q000628:therapy; D005499:Folliculitis / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors*; D016030:Kidney Transplantation; D009260:Nail Diseases / Q000139:chemically induced; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011537:Pruritus / Q000628:therapy; D020123:Sirolimus / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects*; D013281:Stomatitis, Aphthous / Q000139:chemically induced / Q000276:immunology; D058570:TOR Serine-Threonine Kinases; D014657:Vasculitis / Q000139:chemically induced
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D047908:Intracellular Signaling Peptides and Proteins; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus